Search Results for "Benzodiazepine Multiple Sclerosis"

19:45 EST 17th December 2014 | BioPortfolio

Original Source: Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis

This study will use positron emission tomography (PET) to measure a brain protein called peripheral benzodiazepine receptor (PBR) in patients with multiple sclerosis. PBR is created during the inflammation process, and brain inflammation is a key feature of multiple sclerosis (MS). PBR usually affects one type of brain cell, but it can also cause damage to surrounding areas of the brain in patients with MS. PET studies of PBRs and brain inflammation may help elucidate the role...

Matching Channels

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...

Systemic Sclerosis

Diffuse mesangial sclerosis

Amyotrophic lateral sclerosis ALS

B lymphocyte stimulator BlyS

Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.

Matching News

[Articles] Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study

We did not detect KIR4.1-specific IgG in serum or CSF from patients with multiple sclerosis or KIR4.1 loss from glia in multiple sclerosis lesions. Serological testing for KIR4.1-specific IgG is unlik...

Multiple sclerosis drug candidate shows new promise

Positive new data have been released on a drug candidate, RPC1063, for relapsing multiple sclerosis. According to the results from a six-month Phase 2 study of 258 multiple sclerosis patients, the dru...

Multiple sclerosis: First evidence of a rogue protein

A rogue protein has been identified in multiple sclerosis, which attacks the body's central nervous system. Reporting for the first time, researchers believe this finding could pave the way for better...

Multiple Sclerosis Partnering 2009-2014

Recently added to the BioPortfolio report store, Multiple Sclerosis Partnering 2009-2014 is a new report from Current Partnering published on 2014-10-31. This 150+-page report is available from $995....

New research finds the first evidence of a rogue protein in multiple sclerosis

In a new study published today in the journal Frontiers in Neurology, a team of researchers led by the University of Surrey, have identified a rogue protein in multiple sclerosis, which attacks the bo...

Cells from placentas safe for patients with multiple sclerosis

(The Mount Sinai Hospital / Mount Sinai School of Medicine) Patients with multiple sclerosis were able to safely tolerate treatment with cells cultured from human placental tissue, according to a stud...

Cell therapy for multiple sclerosis patients: Closer than ever?

For the first time, scientists generated induced pluripotent stem cells lines from skin samples of patients with primary progressive multiple sclerosis and further, they developed an accelerated proto...

MS drug candidate shows new promise

Positive new data have been released on a drug candidate, RPC1063, for relapsing multiple sclerosis. According to the results from a six-month Phase 2 study of 258 multiple sclerosis patients, the dru...

Matching PubMed Articles

The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis.

Patients with multiple sclerosis (MS) lose brain volume (BV) faster than healthy individuals.

Immunopathology of multiple sclerosis.

Multiple sclerosis is an inflammatory demyelinating disease affecting the central nervous system and considered one of the leading causes of disability in young adults. The precise cause of multiple s...

Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network.

Approximately one-third of those with pediatric-onset multiple sclerosis (MS) experience cognitive impairment. Less is known concerning their change in cognitive functioning over time.

Characterizing cognitive function during relapse in multiple sclerosis.

To characterize neuropsychological (NP) test performance during multiple sclerosis (MS) relapse and recovery.

TIRC7 and HLA-DR axis contributes to inflammation in multiple sclerosis.

Interactions between TIRC7 (a novel seven-transmembrane receptor on activated lymphocytes) and its ligand HLA-DR might be involved in the inflammatory process in multiple sclerosis (MS).

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement